55th Anniversary of IgE Discovery: Pros and Cons of Anti-IgE Treatment
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 30 September 2024 | Viewed by 1049
Special Issue Editors
Interests: allergy and clinical immunology; lung; asthma
Special Issues, Collections and Topics in MDPI journals
Interests: inflammatory mediators; the citokine network (interleukins, chemokines, adhesion molecules, lipoxines); the oxidative stress in various areas of clinical immunology; allergy; oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
IgE is the fifth class of immunoglobulins, discovered in 1967 by Kimishige and Teruko Ishizaka, a married couple of exceptional scientists. Their laboratory findings led to the discovery of IgE, an important step in the process of starting to unravel the mechanisms underlying allergic reactions.
After this discovery, the field of allergy diagnosis and treatment gained increasing interest from scientists, physicians, and the general population.
The industrialization process, which started in the post-World War era, increased this process as higher rates of sensitization were found.
Nowadays, IgE is well known to be elicited by allergens and to be involved in the protection of hosts from helminth infestation. Their function is carried out through interactions with specific receptors and activation mechanisms.
The discovery of anti-IgE treatments such as omalizumab represented a milestone in the treatment of diseases such as severe allergic asthma and chronic spontaneous urticaria, even if the full potential of this drug has yet to be exploited.
This IJMS Special Issue aims to collect a series of articles, either original or reviews, in order to better define the role of anti-IgE treatment.
Prof. Dr. Luisa Ricciardi
Prof. Dr. Sebastiano Gangemi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- IgE
- anti-IgE
- omalizumab
- precision medicine
- allergens
